



IDEAYA Biosciences

Improving Lives
Through Transformative
Precision Medicines

NASDAQ: **IDYA**
October 2024

IDEAYA Highlights

Breakthrough Science on transformative programs in precision medicine, including Synthetic Lethality – an emerging area of precision medicine

Broad Pipeline of potential *first-in-class* precision medicine oncology programs with defined patient biomarkers

Proven Management Team with deep business and scientific experience has built leading oncology companies

Pharma Strategic Partnerships include combinations with Pfizer¹, Amgen¹, Gilead¹, Merck¹, and GSK partnership with ~\$2 billion² in potential milestones

Strong Balance Sheet of ~\$1.2 billion³ with capital efficient model

Analyst Coverage by BTIG, Cantor, Capital One, Citi, Goldman Sachs, Jefferies, JP Morgan, Leerink, LifeSci Capital, Mizuho Securities, Oppenheimer, RBC, Stifel, UBS and Wedbush

- (1) Clinical Trial Collaboration and Supply Agreements, independently with Pfizer (Darovasertib + Crizotinib), Amgen (IDE397 + AMG193), Gilead (IDE397 + Trodelvy®), and Merck (IDE161 + KEYTRUDA®); IDEAYA retains all commercial rights to its products
- (2) GSK Collaboration, Option and License Agreement
- (3) Includes aggregate of \$952.7M cash, cash equivalents and marketable securities as of June 30, 2024, plus pro forma \$283.8M estimated net proceeds from July 2024 public offering